Medicines for Europe has highlighted the need for an improved digital strategy across the EU in order to improve patient information and access to medicines, among other benefits like reducing the risk of supply disruptions, especially in the context of the current pandemic.
“The need to digitalize and to interconnect EU and national medicines agencies,” has been highlighted by Medicines for Europe at a recent webinar, as the European off-patent industry body warned that failing to digitalize might mean that EU digital health and pharmaceutical strategies will miss the mark.
Executive committee member of Medicines for Europe, Markus Sieger commented, “the EU digital strategy can help medicines agencies in all...
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
